| US 7,592,455 B2 | ||
| Bicyclic heteroaromatic compounds as kinase inhibitors | ||
| Daniel Christopher Brookings, Reading (United Kingdom); Jeremy Martin Davis, Wokingham (United Kingdom); and Barry John Langham, Reading (United Kingdom) | ||
| Assigned to UCB Pharma S.A., Brussels (Belgium) | ||
| Appl. No. 10/524,199 PCT Filed Aug. 11, 2003, PCT No. PCT/GB03/03501 § 371(c)(1), (2), (4) Date Jul. 28, 2005, PCT Pub. No. WO2004/014920, PCT Pub. Date Feb. 19, 2004. |
||
| Claims priority of application No. 0218800.1 (GB), filed on Aug. 13, 2002. | ||
| Prior Publication US 2006/0025428 A1, Feb. 02, 2006 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C07D 513/02 (2006.01) | ||
| U.S. Cl. 546—114 | 6 Claims |
1. A compound of formula (1):
![]() the dashed line joining A and C(Ra) is present and represents a bond and A is a —C(Rb)═ group;
Ra and Rb are both hydrogen;
X is —S—;
Y is —C(R10)═ in which R10 is —CONH2, —CONHet1, —CON(R12)Het2, —CON(R12)Alk5Het2 or —CO2Alk6 wherein —NHet1 is pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl or thiazolidinyl, R12 is a hydrogen atom or a straight or branched C1-6 alkyl group, -Het2 is cyclopentyl, cyclohexyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl
or thiazolidinyl, Alk5 is a straight or branched C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene chain, optionally interrupted by one, two or three —O— or —S— atoms or —S(O)—, —S(O)2— or —N(R12)— groups, and Alk6 is C1-4 alkyl;
n is zero or the integer 1;
Alk1 is an aliphatic or heteroaliphatic chain optionally substituted with one, two, three or more substituents where each substituent
may be the same or different and is selected from halogen atoms, —OH, —CO2H, —CO2R4 —CO2CH3, —CON(CH3)3, —CONHR4, —CON(R4)2, —COR4, C1-6 alkoxy, halo(C1-6)alkoxy, —SH, —S(O)R4, —S(O)2R4, C1-6 alkylthio, NHR4, and —N(R4)2, where R4 is an optionally substituted straight or branched C1-6 alkyl group, and such that where two R4 groups are present they may be the same or different and, if attached to an N atom may be joined, together with the N atom
to which they are attached, to form a heterocyclic ring, which heterocyclic ring may be optionally interrupted by a further
heteroatom or heteroatom-containing group selected from —O—, —S—, —N(R4)—, —C(O)— or —C (S)—;
L1 is a covalent bond or a linker atom or group, said linker atom or group being selected from —O—, —S—, —C(O)—,—C(O)O—, —OC(O)—,
—C(S)—, —S(O)—, —S(O)2—, —N(R3)—, —N(R3)O—, —N(R3)NH—, —CON(R3)—, —OC(O)N(R3)—, —CSN (R3)—, —N(R3)CO—, —(R3)C(O)O—, —N(R3)CS—, —S(O)2N (R3)—, —N(R3)S(O)2—, —N(R3)CON(R3)—, —N(R3)CSN(R3)— and —N(R3)SO2N(R3)—, where R3 is a hydrogen atom or a straight or branched alkyl group, and such that where L1 contains two R3 groups these may be the same or different;
Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic,
aromatic or heteroaromatic group, said optional substituent being selected from halogen, C1-6 alkyl, halo(C1-6 alkyl), C1-6 alkoxy, halo(C1-6 alkoxy), cyano, —CO2CH3, —CO2C(CH3)3, nitro, amino, —NHCH3, —N(CH3)2, —COCH3 and —NHCOCH3;
L is an atom or chain —(CH2)pHet(CH2)q—;
p and q, which may be the same or different, are each zero or the integer 1;
Het is an —O— or —S— atom or a —C(R3a)(R3b)—, —C(O)—, —C(O)O—, —OC(O)—, —C(S)—, —S(O)—, —S(O)2—, —N(R3c)O—, —N(R3c)NH—, —N(R3c)C(R3a)(R3b)—, —CON(R3c)—, —OC(O)N(R3c)—, —CSN(R3c)—, —N(R3c)CO—, —N(R3c)C(O)O—, —N(R3c)CS—, —S(O)2N(R3c)—, —N(R3c)S(O)2—, —N(R3c)CON(R3d)—, —N(R3c)CSN(R3d)— or —N(R3c)S(O)2N(R3d)— group and, when one or both of p and q is the integer 1, Het is additionally a —N(R3c)— group;
R3a and R3b are each independently a hydrogen atom, —OH, or an optionally substituted C1-6 alkyl group;
R3c and R3d are each independently a hydrogen atom or a straight or branched alkyl group;
Ar is an optionally substituted aromatic or heteroaromatic group; or a pharmaceutically acceptable salt thereof.
|